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Supplementary CON 0.3 ± 0.2 1.3 ± 0.3 4.9 ± 3.1 17.6 ± 9.1 10.1 ± 1.6 24.0 ± 19.2 PCAD 0.3 ± 0.1 1.6 ± 0.2 2.6 ± 0.9 19.8 ± 6.3 13.0 ± 1.3 44.0 ± 20.6 MCI 0.4 ± 0.1 1.2 ± 0.5 3.1 ± 0.6 16.0 ± 6.1 27.3 ± 4.1 116 ± 82.4 AD 0.6 ± 0.3 2.0 ± 0.3 111 ± 52.5 * 1032 ± 131 * 310 ± 108.3 * 98.7 ± 16.5 FTD 0.3 ± 0.1 1.3 ± 0.6 3.1 ± 0.7 0.0 ± 0.0 18.0 ± 1.5 18.3 ± 19.2 Cerebellum CON 0.2 ± 0.0 2.1 ± 0.2 7.9 ± 1.6 0.7 ± 0.7 12.2 ± 1.3 2.5 ± 2.5 PCAD 0.2 ± 0.1 1.6 ± 0.3 11.4 ± 0.9 0.2 ± 0.2 13.4 ± 1.2 2.2 ± 1.5 MCI 0.0 ± 0.0 0.8 ± 0.3 11.1 ± 0.9 1.2 ± 1.0 14.8 ± 3.0 0.0 ± 0.0 AD 0.4 ± 0.2 1.2 ± 0.3 53.8 ± 28.8 62.0 ± 5.3 * 544 ± 328.7 87.9 ± 37.6 * FTD 0.0 ± 0.0
Values are given in pmol/g (see main text for a description of the methods). * p < 0.05, Dunnett's test (relative to control group). AD, Alzheimer's disease; A␤, amyloid-␤; CON, control; FA, formic acid; FTD, frontotemporal dementia; MCI, mild cognitive impairment; PBS, phosphate buffered saline; PCAD; preclinical Alzheimer's disease; SDS, sodium dodecyl sulfate.
